#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0089] Still other methods describe making embryoid bodies (EBs).
1-1	0-1	[	_	_	
1-2	1-5	0089	_	_	
1-3	5-6	]	_	_	
1-4	7-12	Still	_	_	
1-5	13-18	other	_	_	
1-6	19-26	methods	_	_	
1-7	27-35	describe	_	_	
1-8	36-42	making	_	_	
1-9	43-51	embryoid	_	_	
1-10	52-58	bodies	_	_	
1-11	59-60	(	_	_	
1-12	60-63	EBs	_	_	
1-13	63-64	)	_	_	
1-14	64-65	.	_	_	

#Text=As used herein, the term "embryoid bodies", "aggregate bodies" or equivalents thereof, refer to aggregates of differentiated and undifferentiated cells that appear when ES cells overgrow in monolayer cultures, or are maintained in suspension cultures in undefined media or are differentiated via non-directed protocols towards multiple germ layer tissues.
2-1	66-68	As	_	_	
2-2	69-73	used	_	_	
2-3	74-80	herein	_	_	
2-4	80-81	,	_	_	
2-5	82-85	the	_	_	
2-6	86-90	term	_	_	
2-7	91-92	"	_	_	
2-8	92-100	embryoid	_	_	
2-9	101-107	bodies	_	_	
2-10	107-108	"	_	_	
2-11	108-109	,	_	_	
2-12	110-111	"	_	_	
2-13	111-120	aggregate	_	_	
2-14	121-127	bodies	_	_	
2-15	127-128	"	_	_	
2-16	129-131	or	_	_	
2-17	132-143	equivalents	_	_	
2-18	144-151	thereof	_	_	
2-19	151-152	,	_	_	
2-20	153-158	refer	_	_	
2-21	159-161	to	_	_	
2-22	162-172	aggregates	_	_	
2-23	173-175	of	_	_	
2-24	176-190	differentiated	_	_	
2-25	191-194	and	_	_	
2-26	195-211	undifferentiated	_	_	
2-27	212-217	cells	_	_	
2-28	218-222	that	_	_	
2-29	223-229	appear	_	_	
2-30	230-234	when	_	_	
2-31	235-237	ES	_	_	
2-32	238-243	cells	_	_	
2-33	244-252	overgrow	_	_	
2-34	253-255	in	_	_	
2-35	256-265	monolayer	_	_	
2-36	266-274	cultures	_	_	
2-37	274-275	,	_	_	
2-38	276-278	or	_	_	
2-39	279-282	are	_	_	
2-40	283-293	maintained	_	_	
2-41	294-296	in	_	_	
2-42	297-307	suspension	_	_	
2-43	308-316	cultures	_	_	
2-44	317-319	in	_	_	
2-45	320-329	undefined	_	_	
2-46	330-335	media	_	_	
2-47	336-338	or	_	_	
2-48	339-342	are	_	_	
2-49	343-357	differentiated	_	_	
2-50	358-361	via	_	_	
2-51	362-374	non-directed	_	_	
2-52	375-384	protocols	_	_	
2-53	385-392	towards	_	_	
2-54	393-401	multiple	_	_	
2-55	402-406	germ	_	_	
2-56	407-412	layer	_	_	
2-57	413-420	tissues	_	_	
2-58	420-421	.	_	_	

#Text=That is, EBs are not formed from a single cell suspension of pluripotent stem cells as described herein; nor are EBs formed from adherent cultures of hES-derived multipotent cells.
3-1	422-426	That	_	_	
3-2	427-429	is	_	_	
3-3	429-430	,	_	_	
3-4	431-434	EBs	_	_	
3-5	435-438	are	_	_	
3-6	439-442	not	_	_	
3-7	443-449	formed	_	_	
3-8	450-454	from	_	_	
3-9	455-456	a	_	_	
3-10	457-463	single	_	_	
3-11	464-468	cell	_	_	
3-12	469-479	suspension	_	_	
3-13	480-482	of	_	_	
3-14	483-494	pluripotent	_	_	
3-15	495-499	stem	_	_	
3-16	500-505	cells	_	_	
3-17	506-508	as	_	_	
3-18	509-518	described	_	_	
3-19	519-525	herein	_	_	
3-20	525-526	;	_	_	
3-21	527-530	nor	_	_	
3-22	531-534	are	_	_	
3-23	535-538	EBs	_	_	
3-24	539-545	formed	_	_	
3-25	546-550	from	_	_	
3-26	551-559	adherent	_	_	
3-27	560-568	cultures	_	_	
3-28	569-571	of	_	_	
3-29	572-583	hES-derived	_	_	
3-30	584-595	multipotent	_	_	
3-31	596-601	cells	_	_	
3-32	601-602	.	_	_	

#Text=These features alone make the present invention clearly distinguished from an embryoid body.
#Text=[0090] Embryoid bodies are a mixture of different cell types, typically from several germ layers, distinguishable by morphological criteria.
4-1	603-608	These	_	_	
4-2	609-617	features	_	_	
4-3	618-623	alone	_	_	
4-4	624-628	make	_	_	
4-5	629-632	the	_	_	
4-6	633-640	present	_	_	
4-7	641-650	invention	_	_	
4-8	651-658	clearly	_	_	
4-9	659-672	distinguished	_	_	
4-10	673-677	from	_	_	
4-11	678-680	an	_	_	
4-12	681-689	embryoid	_	_	
4-13	690-694	body	_	_	
4-14	694-695	.	_	_	
4-15	696-697	[	_	_	
4-16	697-701	0090	_	_	
4-17	701-702	]	_	_	
4-18	703-711	Embryoid	_	_	
4-19	712-718	bodies	_	_	
4-20	719-722	are	_	_	
4-21	723-724	a	_	_	
4-22	725-732	mixture	_	_	
4-23	733-735	of	_	_	
4-24	736-745	different	_	_	
4-25	746-750	cell	_	_	
4-26	751-756	types	_	_	
4-27	756-757	,	_	_	
4-28	758-767	typically	_	_	
4-29	768-772	from	_	_	
4-30	773-780	several	_	_	
4-31	781-785	germ	_	_	
4-32	786-792	layers	_	_	
4-33	792-793	,	_	_	
4-34	794-809	distinguishable	_	_	
4-35	810-812	by	_	_	
4-36	813-826	morphological	_	_	
4-37	827-835	criteria	_	_	
4-38	835-836	.	_	_	

#Text=Embryoid bodies typically refer to a morphological structure comprised of a population of cells, the majority of which are derived from embryonic stem (ES) cells that have undergone non-directed differentiation, i.e., such as that which occurs when undifferentiated cells are exposed to high concentrations of serum in the absence of defined growth factors.
5-1	837-845	Embryoid	_	_	
5-2	846-852	bodies	_	_	
5-3	853-862	typically	_	_	
5-4	863-868	refer	_	_	
5-5	869-871	to	_	_	
5-6	872-873	a	_	_	
5-7	874-887	morphological	_	_	
5-8	888-897	structure	_	_	
5-9	898-907	comprised	_	_	
5-10	908-910	of	_	_	
5-11	911-912	a	_	_	
5-12	913-923	population	_	_	
5-13	924-926	of	_	_	
5-14	927-932	cells	_	_	
5-15	932-933	,	_	_	
5-16	934-937	the	_	_	
5-17	938-946	majority	_	_	
5-18	947-949	of	_	_	
5-19	950-955	which	_	_	
5-20	956-959	are	_	_	
5-21	960-967	derived	_	_	
5-22	968-972	from	_	_	
5-23	973-982	embryonic	_	_	
5-24	983-987	stem	_	_	
5-25	988-989	(	_	_	
5-26	989-991	ES	_	_	
5-27	991-992	)	_	_	
5-28	993-998	cells	_	_	
5-29	999-1003	that	_	_	
5-30	1004-1008	have	_	_	
5-31	1009-1018	undergone	_	_	
5-32	1019-1031	non-directed	_	_	
5-33	1032-1047	differentiation	_	_	
5-34	1047-1048	,	_	_	
5-35	1049-1052	i.e	_	_	
5-36	1052-1053	.	_	_	
5-37	1053-1054	,	_	_	
5-38	1055-1059	such	_	_	
5-39	1060-1062	as	_	_	
5-40	1063-1067	that	_	_	
5-41	1068-1073	which	_	_	
5-42	1074-1080	occurs	_	_	
5-43	1081-1085	when	_	_	
5-44	1086-1102	undifferentiated	_	_	
5-45	1103-1108	cells	_	_	
5-46	1109-1112	are	_	_	
5-47	1113-1120	exposed	_	_	
5-48	1121-1123	to	_	_	
5-49	1124-1128	high	_	_	
5-50	1129-1143	concentrations	_	_	
5-51	1144-1146	of	_	_	
5-52	1147-1152	serum	_	_	
5-53	1153-1155	in	_	_	
5-54	1156-1159	the	_	_	
5-55	1160-1167	absence	_	_	
5-56	1168-1170	of	_	_	
5-57	1171-1178	defined	_	_	
5-58	1179-1185	growth	_	_	
5-59	1186-1193	factors	_	_	
5-60	1193-1194	.	_	_	

#Text=Under culture conditions suitable for EB formation (e.g., the removal of Leukemia inhibitory factor for mouse ES cells, or other, similar blocking factors), ES cells proliferate and form small masses of cells that begin to differentiate.
6-1	1195-1200	Under	_	_	
6-2	1201-1208	culture	_	_	
6-3	1209-1219	conditions	_	_	
6-4	1220-1228	suitable	_	_	
6-5	1229-1232	for	_	_	
6-6	1233-1235	EB	_	_	
6-7	1236-1245	formation	_	_	
6-8	1246-1247	(	_	_	
6-9	1247-1250	e.g	_	_	
6-10	1250-1251	.	_	_	
6-11	1251-1252	,	_	_	
6-12	1253-1256	the	_	_	
6-13	1257-1264	removal	_	_	
6-14	1265-1267	of	_	_	
6-15	1268-1276	Leukemia	_	_	
6-16	1277-1287	inhibitory	_	_	
6-17	1288-1294	factor	_	_	
6-18	1295-1298	for	_	_	
6-19	1299-1304	mouse	_	_	
6-20	1305-1307	ES	_	_	
6-21	1308-1313	cells	_	_	
6-22	1313-1314	,	_	_	
6-23	1315-1317	or	_	_	
6-24	1318-1323	other	_	_	
6-25	1323-1324	,	_	_	
6-26	1325-1332	similar	_	_	
6-27	1333-1341	blocking	_	_	
6-28	1342-1349	factors	_	_	
6-29	1349-1350	)	_	_	
6-30	1350-1351	,	_	_	
6-31	1352-1354	ES	_	_	
6-32	1355-1360	cells	_	_	
6-33	1361-1372	proliferate	_	_	
6-34	1373-1376	and	_	_	
6-35	1377-1381	form	_	_	
6-36	1382-1387	small	_	_	
6-37	1388-1394	masses	_	_	
6-38	1395-1397	of	_	_	
6-39	1398-1403	cells	_	_	
6-40	1404-1408	that	_	_	
6-41	1409-1414	begin	_	_	
6-42	1415-1417	to	_	_	
6-43	1418-1431	differentiate	_	_	
6-44	1431-1432	.	_	_	

#Text=First, corresponding to about days 1-4 of differentiation for human ES cells, the small mass of cells forms a layer of endodermal cells on the outer layer, and is considered a "simple embryoid body".
7-1	1433-1438	First	_	_	
7-2	1438-1439	,	_	_	
7-3	1440-1453	corresponding	_	_	
7-4	1454-1456	to	_	_	
7-5	1457-1462	about	_	_	
7-6	1463-1467	days	_	_	
7-7	1468-1469	1	_	_	
7-8	1469-1470	-	_	_	
7-9	1470-1471	4	_	_	
7-10	1472-1474	of	_	_	
7-11	1475-1490	differentiation	_	_	
7-12	1491-1494	for	_	_	
7-13	1495-1500	human	_	_	
7-14	1501-1503	ES	_	_	
7-15	1504-1509	cells	_	_	
7-16	1509-1510	,	_	_	
7-17	1511-1514	the	_	_	
7-18	1515-1520	small	_	_	
7-19	1521-1525	mass	_	_	
7-20	1526-1528	of	_	_	
7-21	1529-1534	cells	_	_	
7-22	1535-1540	forms	_	_	
7-23	1541-1542	a	_	_	
7-24	1543-1548	layer	_	_	
7-25	1549-1551	of	_	_	
7-26	1552-1562	endodermal	_	_	
7-27	1563-1568	cells	_	_	
7-28	1569-1571	on	_	_	
7-29	1572-1575	the	_	_	
7-30	1576-1581	outer	_	_	
7-31	1582-1587	layer	_	_	
7-32	1587-1588	,	_	_	
7-33	1589-1592	and	_	_	
7-34	1593-1595	is	_	_	
7-35	1596-1606	considered	_	_	
7-36	1607-1608	a	_	_	
7-37	1609-1610	"	_	_	
7-38	1610-1616	simple	_	_	
7-39	1617-1625	embryoid	_	_	
7-40	1626-1630	body	_	_	
7-41	1630-1631	"	_	_	
7-42	1631-1632	.	_	_	

#Text=Secondly, corresponding to about days 3-20 post differentiation for human ES cells, "complex embryoid bodies" are formed, which are characterized by extensive differentiation of ectodermal and mesodermal cells and derivative tissue.
8-1	1633-1641	Secondly	_	_	
8-2	1641-1642	,	_	_	
8-3	1643-1656	corresponding	_	_	
8-4	1657-1659	to	_	_	
8-5	1660-1665	about	_	_	
8-6	1666-1670	days	_	_	
8-7	1671-1672	3	_	_	
8-8	1672-1673	-	_	_	
8-9	1673-1675	20	_	_	
8-10	1676-1680	post	_	_	
8-11	1681-1696	differentiation	_	_	
8-12	1697-1700	for	_	_	
8-13	1701-1706	human	_	_	
8-14	1707-1709	ES	_	_	
8-15	1710-1715	cells	_	_	
8-16	1715-1716	,	_	_	
8-17	1717-1718	"	_	_	
8-18	1718-1725	complex	_	_	
8-19	1726-1734	embryoid	_	_	
8-20	1735-1741	bodies	_	_	
8-21	1741-1742	"	_	_	
8-22	1743-1746	are	_	_	
8-23	1747-1753	formed	_	_	
8-24	1753-1754	,	_	_	
8-25	1755-1760	which	_	_	
8-26	1761-1764	are	_	_	
8-27	1765-1778	characterized	_	_	
8-28	1779-1781	by	_	_	
8-29	1782-1791	extensive	_	_	
8-30	1792-1807	differentiation	_	_	
8-31	1808-1810	of	_	_	
8-32	1811-1821	ectodermal	_	_	
8-33	1822-1825	and	_	_	
8-34	1826-1836	mesodermal	_	_	
8-35	1837-1842	cells	_	_	
8-36	1843-1846	and	_	_	
8-37	1847-1857	derivative	_	_	
8-38	1858-1864	tissue	_	_	
8-39	1864-1865	.	_	_	

#Text=As used herein, EBs includes both simple and complex EBs unless otherwise required by context.
9-1	1866-1868	As	_	_	
9-2	1869-1873	used	_	_	
9-3	1874-1880	herein	_	_	
9-4	1880-1881	,	_	_	
9-5	1882-1885	EBs	_	_	
9-6	1886-1894	includes	_	_	
9-7	1895-1899	both	_	_	
9-8	1900-1906	simple	_	_	
9-9	1907-1910	and	_	_	
9-10	1911-1918	complex	_	_	
9-11	1919-1922	EBs	_	_	
9-12	1923-1929	unless	_	_	
9-13	1930-1939	otherwise	_	_	
9-14	1940-1948	required	_	_	
9-15	1949-1951	by	_	_	
9-16	1952-1959	context	_	_	
9-17	1959-1960	.	_	_	

#Text=The determination of when embryoid bodies have formed in a culture of ES cells is routinely made by persons of skill in the art by, for example, visual inspection of the morphology.
10-1	1961-1964	The	_	_	
10-2	1965-1978	determination	_	_	
10-3	1979-1981	of	_	_	
10-4	1982-1986	when	_	_	
10-5	1987-1995	embryoid	_	_	
10-6	1996-2002	bodies	_	_	
10-7	2003-2007	have	_	_	
10-8	2008-2014	formed	_	_	
10-9	2015-2017	in	_	_	
10-10	2018-2019	a	_	_	
10-11	2020-2027	culture	_	_	
10-12	2028-2030	of	_	_	
10-13	2031-2033	ES	_	_	
10-14	2034-2039	cells	_	_	
10-15	2040-2042	is	_	_	
10-16	2043-2052	routinely	_	_	
10-17	2053-2057	made	_	_	
10-18	2058-2060	by	_	_	
10-19	2061-2068	persons	_	_	
10-20	2069-2071	of	_	_	
10-21	2072-2077	skill	_	_	
10-22	2078-2080	in	_	_	
10-23	2081-2084	the	_	_	
10-24	2085-2088	art	_	_	
10-25	2089-2091	by	_	_	
10-26	2091-2092	,	_	_	
10-27	2093-2096	for	_	_	
10-28	2097-2104	example	_	_	
10-29	2104-2105	,	_	_	
10-30	2106-2112	visual	_	_	
10-31	2113-2123	inspection	_	_	
10-32	2124-2126	of	_	_	
10-33	2127-2130	the	_	_	
10-34	2131-2141	morphology	_	_	
10-35	2141-2142	.	_	_	

#Text=Floating masses of about 20 cells or more depending on the culture conditions are considered to be EBs.
11-1	2143-2151	Floating	_	_	
11-2	2152-2158	masses	_	_	
11-3	2159-2161	of	_	_	
11-4	2162-2167	about	_	_	
11-5	2168-2170	20	_	_	
11-6	2171-2176	cells	_	_	
11-7	2177-2179	or	_	_	
11-8	2180-2184	more	_	_	
11-9	2185-2194	depending	_	_	
11-10	2195-2197	on	_	_	
11-11	2198-2201	the	_	_	
11-12	2202-2209	culture	_	_	
11-13	2210-2220	conditions	_	_	
11-14	2221-2224	are	_	_	
11-15	2225-2235	considered	_	_	
11-16	2236-2238	to	_	_	
11-17	2239-2241	be	_	_	
11-18	2242-2245	EBs	_	_	
11-19	2245-2246	.	_	_	

#Text=See, e.g., Schmitt et al. (1991) Genes Dev. 5, 728-740; Doetschman et al. (1985) J.
12-1	2247-2250	See	_	_	
12-2	2250-2251	,	_	_	
12-3	2252-2255	e.g	_	_	
12-4	2255-2256	.	_	_	
12-5	2256-2257	,	_	_	
12-6	2258-2265	Schmitt	_	_	
12-7	2266-2268	et	_	_	
12-8	2269-2271	al	_	_	
12-9	2271-2272	.	_	_	
12-10	2273-2274	(	_	_	
12-11	2274-2278	1991	_	_	
12-12	2278-2279	)	_	_	
12-13	2280-2285	Genes	_	_	
12-14	2286-2289	Dev	_	_	
12-15	2289-2290	.	_	_	
12-16	2291-2292	5	_	_	
12-17	2292-2293	,	_	_	
12-18	2294-2297	728	_	_	
12-19	2297-2298	-	_	_	
12-20	2298-2301	740	_	_	
12-21	2301-2302	;	_	_	
12-22	2303-2313	Doetschman	_	_	
12-23	2314-2316	et	_	_	
12-24	2317-2319	al	_	_	
12-25	2319-2320	.	_	_	
12-26	2321-2322	(	_	_	
12-27	2322-2326	1985	_	_	
12-28	2326-2327	)	_	_	
12-29	2328-2329	J	_	_	
12-30	2329-2330	.	_	_	

#Text=Embryol.
13-1	2331-2338	Embryol	_	_	
13-2	2338-2339	.	_	_	

#Text=Exp.
14-1	2340-2343	Exp	_	_	
14-2	2343-2344	.	_	_	

#Text=Morph. 87, 27-45.
15-1	2345-2350	Morph	_	_	
15-2	2350-2351	.	_	_	
15-3	2352-2354	87	_	_	
15-4	2354-2355	,	_	_	
15-5	2356-2358	27	_	_	
15-6	2358-2359	-	_	_	
15-7	2359-2361	45	_	_	
15-8	2361-2362	.	_	_	

#Text=The term also refers to equivalent structures derived from primordial germ cells, which are primitive cells extracted from embryonic gonadal regions; see, e.g., Shamblott, et al. (1998) Proc.
16-1	2363-2366	The	_	_	
16-2	2367-2371	term	_	_	
16-3	2372-2376	also	_	_	
16-4	2377-2383	refers	_	_	
16-5	2384-2386	to	_	_	
16-6	2387-2397	equivalent	_	_	
16-7	2398-2408	structures	_	_	
16-8	2409-2416	derived	_	_	
16-9	2417-2421	from	_	_	
16-10	2422-2432	primordial	_	_	
16-11	2433-2437	germ	_	_	
16-12	2438-2443	cells	_	_	
16-13	2443-2444	,	_	_	
16-14	2445-2450	which	_	_	
16-15	2451-2454	are	_	_	
16-16	2455-2464	primitive	_	_	
16-17	2465-2470	cells	_	_	
16-18	2471-2480	extracted	_	_	
16-19	2481-2485	from	_	_	
16-20	2486-2495	embryonic	_	_	
16-21	2496-2503	gonadal	_	_	
16-22	2504-2511	regions	_	_	
16-23	2511-2512	;	_	_	
16-24	2513-2516	see	_	_	
16-25	2516-2517	,	_	_	
16-26	2518-2521	e.g	_	_	
16-27	2521-2522	.	_	_	
16-28	2522-2523	,	_	_	
16-29	2524-2533	Shamblott	_	_	
16-30	2533-2534	,	_	_	
16-31	2535-2537	et	_	_	
16-32	2538-2540	al	_	_	
16-33	2540-2541	.	_	_	
16-34	2542-2543	(	_	_	
16-35	2543-2547	1998	_	_	
16-36	2547-2548	)	_	_	
16-37	2549-2553	Proc	_	_	
16-38	2553-2554	.	_	_	

#Text=Natl.
17-1	2555-2559	Natl	_	_	
17-2	2559-2560	.	_	_	

#Text=Acad.
18-1	2561-2565	Acad	_	_	
18-2	2565-2566	.	_	_	

#Text=Sci.
19-1	2567-2570	Sci	_	_	
19-2	2570-2571	.	_	_	

#Text=USA 95, 13726.
20-1	2572-2575	USA	_	_	
20-2	2576-2578	95	_	_	
20-3	2578-2579	,	_	_	
20-4	2580-2585	13726	_	_	
20-5	2585-2586	.	_	_	

#Text=Primordial germ cells, sometimes also referred to in the art as EG cells or embryonic germ cells, when treated with appropriate factors form pluripotent ES cells from which embryoid bodies can be derived; see, e.g., U.S.
21-1	2587-2597	Primordial	_	_	
21-2	2598-2602	germ	_	_	
21-3	2603-2608	cells	_	_	
21-4	2608-2609	,	_	_	
21-5	2610-2619	sometimes	_	_	
21-6	2620-2624	also	_	_	
21-7	2625-2633	referred	_	_	
21-8	2634-2636	to	_	_	
21-9	2637-2639	in	_	_	
21-10	2640-2643	the	_	_	
21-11	2644-2647	art	_	_	
21-12	2648-2650	as	_	_	
21-13	2651-2653	EG	_	_	
21-14	2654-2659	cells	_	_	
21-15	2660-2662	or	_	_	
21-16	2663-2672	embryonic	_	_	
21-17	2673-2677	germ	_	_	
21-18	2678-2683	cells	_	_	
21-19	2683-2684	,	_	_	
21-20	2685-2689	when	_	_	
21-21	2690-2697	treated	_	_	
21-22	2698-2702	with	_	_	
21-23	2703-2714	appropriate	_	_	
21-24	2715-2722	factors	_	_	
21-25	2723-2727	form	_	_	
21-26	2728-2739	pluripotent	_	_	
21-27	2740-2742	ES	_	_	
21-28	2743-2748	cells	_	_	
21-29	2749-2753	from	_	_	
21-30	2754-2759	which	_	_	
21-31	2760-2768	embryoid	_	_	
21-32	2769-2775	bodies	_	_	
21-33	2776-2779	can	_	_	
21-34	2780-2782	be	_	_	
21-35	2783-2790	derived	_	_	
21-36	2790-2791	;	_	_	
21-37	2792-2795	see	_	_	
21-38	2795-2796	,	_	_	
21-39	2797-2800	e.g	_	_	
21-40	2800-2801	.	_	_	
21-41	2801-2802	,	_	_	
21-42	2803-2806	U.S	_	_	
21-43	2806-2807	.	_	_	

#Text=Pat.
22-1	2808-2811	Pat	_	_	
22-2	2811-2812	.	_	_	

#Text=No. 5,670,372; and Shamblott, et al., supra.
#Text=[0091] Various methods for making EBs exist, e.g. spin embryoid bodies as described by Ng et a. (2008) Nature Protocols 3(5): 468-776 and EBs made from single cell suspensions which were plated onto micro-patterned extracellular matrix islands as described in Bauwens et al (2008) supra.
23-1	2813-2815	No	_	_	
23-2	2815-2816	.	_	_	
23-3	2817-2826	5,670,372	_	_	
23-4	2826-2827	;	_	_	
23-5	2828-2831	and	_	_	
23-6	2832-2841	Shamblott	_	_	
23-7	2841-2842	,	_	_	
23-8	2843-2845	et	_	_	
23-9	2846-2848	al	_	_	
23-10	2848-2849	.	_	_	
23-11	2849-2850	,	_	_	
23-12	2851-2856	supra	_	_	
23-13	2856-2857	.	_	_	
23-14	2858-2859	[	*[1]	26-6[2_1]	
23-15	2859-2863	0091	*[1]	_	
23-16	2863-2864	]	*[1]	_	
23-17	2865-2872	Various	*[1]	_	
23-18	2873-2880	methods	*[1]	_	
23-19	2881-2884	for	*[1]	_	
23-20	2885-2891	making	*[1]	_	
23-21	2892-2895	EBs	*[1]	_	
23-22	2896-2901	exist	*[1]	_	
23-23	2901-2902	,	*[1]	_	
23-24	2903-2906	e.g	*[1]	_	
23-25	2906-2907	.	*[1]	_	
23-26	2908-2912	spin	*[1]	_	
23-27	2913-2921	embryoid	*[1]	_	
23-28	2922-2928	bodies	*[1]	_	
23-29	2929-2931	as	*[1]	_	
23-30	2932-2941	described	*[1]	_	
23-31	2942-2944	by	*[1]	_	
23-32	2945-2947	Ng	*[1]	_	
23-33	2948-2950	et	*[1]	_	
23-34	2951-2952	a	*[1]	_	
23-35	2952-2953	.	*[1]	_	
23-36	2954-2955	(	*[1]	_	
23-37	2955-2959	2008	*[1]	_	
23-38	2959-2960	)	*[1]	_	
23-39	2961-2967	Nature	*[1]	_	
23-40	2968-2977	Protocols	*[1]	_	
23-41	2978-2979	3	*[1]	_	
23-42	2979-2980	(	*[1]	_	
23-43	2980-2981	5	*[1]	_	
23-44	2981-2982	)	*[1]	_	
23-45	2982-2983	:	*[1]	_	
23-46	2984-2987	468	*[1]	_	
23-47	2987-2988	-	*[1]	_	
23-48	2988-2991	776	*[1]	_	
23-49	2992-2995	and	*[1]	_	
23-50	2996-2999	EBs	*[1]	_	
23-51	3000-3004	made	*[1]	_	
23-52	3005-3009	from	*[1]	_	
23-53	3010-3016	single	*[1]	_	
23-54	3017-3021	cell	*[1]	_	
23-55	3022-3033	suspensions	*[1]	_	
23-56	3034-3039	which	*[1]	_	
23-57	3040-3044	were	*[1]	_	
23-58	3045-3051	plated	*[1]	_	
23-59	3052-3056	onto	*[1]	_	
23-60	3057-3072	micro-patterned	*[1]	_	
23-61	3073-3086	extracellular	*[1]	_	
23-62	3087-3093	matrix	*[1]	_	
23-63	3094-3101	islands	*[1]	_	
23-64	3102-3104	as	*[1]	_	
23-65	3105-3114	described	*[1]	_	
23-66	3115-3117	in	*[1]	_	
23-67	3118-3125	Bauwens	*[1]	_	
23-68	3126-3128	et	*[1]	_	
23-69	3129-3131	al	*[1]	_	
23-70	3132-3133	(	*[1]	_	
23-71	3133-3137	2008	*[1]	_	
23-72	3137-3138	)	*[1]	_	
23-73	3139-3144	supra	*[1]	_	
23-74	3144-3145	.	*[1]	_	

#Text=However, these methods are cost-prohibitive and less efficient for large scaled production (manufacturing) of hES cells and hES-derived cells because they require too many steps before scale-up production can actually commence.
24-1	3146-3153	However	_	_	
24-2	3153-3154	,	_	_	
24-3	3155-3160	these	_	_	
24-4	3161-3168	methods	_	_	
24-5	3169-3172	are	_	_	
24-6	3173-3189	cost-prohibitive	_	_	
24-7	3190-3193	and	_	_	
24-8	3194-3198	less	_	_	
24-9	3199-3208	efficient	_	_	
24-10	3209-3212	for	_	_	
24-11	3213-3218	large	_	_	
24-12	3219-3225	scaled	_	_	
24-13	3226-3236	production	_	_	
24-14	3237-3238	(	_	_	
24-15	3238-3251	manufacturing	_	_	
24-16	3251-3252	)	_	_	
24-17	3253-3255	of	_	_	
24-18	3256-3259	hES	_	_	
24-19	3260-3265	cells	_	_	
24-20	3266-3269	and	_	_	
24-21	3270-3281	hES-derived	_	_	
24-22	3282-3287	cells	_	_	
24-23	3288-3295	because	_	_	
24-24	3296-3300	they	_	_	
24-25	3301-3308	require	_	_	
24-26	3309-3312	too	_	_	
24-27	3313-3317	many	_	_	
24-28	3318-3323	steps	_	_	
24-29	3324-3330	before	_	_	
24-30	3331-3339	scale-up	_	_	
24-31	3340-3350	production	_	_	
24-32	3351-3354	can	_	_	
24-33	3355-3363	actually	_	_	
24-34	3364-3372	commence	_	_	
24-35	3372-3373	.	_	_	

#Text=For example, Bauwens et al., first have to seed hES cells on a growth factor reduced MATRIGEL.TM. before the cells can be selected to start a suspension culture.
25-1	3374-3377	For	_	_	
25-2	3378-3385	example	_	_	
25-3	3385-3386	,	_	_	
25-4	3387-3394	Bauwens	_	_	
25-5	3395-3397	et	_	_	
25-6	3398-3400	al	_	_	
25-7	3400-3401	.	_	_	
25-8	3401-3402	,	_	_	
25-9	3403-3408	first	_	_	
25-10	3409-3413	have	_	_	
25-11	3414-3416	to	_	_	
25-12	3417-3421	seed	_	_	
25-13	3422-3425	hES	_	_	
25-14	3426-3431	cells	_	_	
25-15	3432-3434	on	_	_	
25-16	3435-3436	a	_	_	
25-17	3437-3443	growth	_	_	
25-18	3444-3450	factor	_	_	
25-19	3451-3458	reduced	_	_	
25-20	3459-3470	MATRIGEL.TM	_	_	
25-21	3470-3471	.	_	_	
25-22	3472-3478	before	_	_	
25-23	3479-3482	the	_	_	
25-24	3483-3488	cells	_	_	
25-25	3489-3492	can	_	_	
25-26	3493-3495	be	_	_	
25-27	3496-3504	selected	_	_	
25-28	3505-3507	to	_	_	
25-29	3508-3513	start	_	_	
25-30	3514-3515	a	_	_	
25-31	3516-3526	suspension	_	_	
25-32	3527-3534	culture	_	_	
25-33	3534-3535	.	_	_	

#Text=The time and cost of this method makes it cumbersome because customized micro-patterned tissue culture plates are required.
26-1	3536-3539	The	_	_	
26-2	3540-3544	time	_	_	
26-3	3545-3548	and	_	_	
26-4	3549-3553	cost	_	_	
26-5	3554-3556	of	_	_	
26-6	3557-3561	this	*[2]	_	
26-7	3562-3568	method	*[2]	_	
26-8	3569-3574	makes	_	_	
26-9	3575-3577	it	_	_	
26-10	3578-3588	cumbersome	_	_	
26-11	3589-3596	because	_	_	
26-12	3597-3607	customized	_	_	
26-13	3608-3623	micro-patterned	_	_	
26-14	3624-3630	tissue	_	_	
26-15	3631-3638	culture	_	_	
26-16	3639-3645	plates	_	_	
26-17	3646-3649	are	_	_	
26-18	3650-3658	required	_	_	
26-19	3658-3659	.	_	_	

#Text=Additionally, the method employed by Ng et al. is also not cost-efficient for large scale-up manufacturing of hES cells and hES-derived cells because of the use of centrifuges in order to create a more uniform EB.
27-1	3660-3672	Additionally	_	_	
27-2	3672-3673	,	_	_	
27-3	3674-3677	the	_	_	
27-4	3678-3684	method	_	_	
27-5	3685-3693	employed	_	_	
27-6	3694-3696	by	_	_	
27-7	3697-3699	Ng	_	_	
27-8	3700-3702	et	_	_	
27-9	3703-3705	al	_	_	
27-10	3705-3706	.	_	_	
27-11	3707-3709	is	_	_	
27-12	3710-3714	also	_	_	
27-13	3715-3718	not	_	_	
27-14	3719-3733	cost-efficient	_	_	
27-15	3734-3737	for	_	_	
27-16	3738-3743	large	_	_	
27-17	3744-3752	scale-up	_	_	
27-18	3753-3766	manufacturing	_	_	
27-19	3767-3769	of	_	_	
27-20	3770-3773	hES	_	_	
27-21	3774-3779	cells	_	_	
27-22	3780-3783	and	_	_	
27-23	3784-3795	hES-derived	_	_	
27-24	3796-3801	cells	_	_	
27-25	3802-3809	because	_	_	
27-26	3810-3812	of	_	_	
27-27	3813-3816	the	_	_	
27-28	3817-3820	use	_	_	
27-29	3821-3823	of	_	_	
27-30	3824-3835	centrifuges	_	_	
27-31	3836-3838	in	_	_	
27-32	3839-3844	order	_	_	
27-33	3845-3847	to	_	_	
27-34	3848-3854	create	_	_	
27-35	3855-3856	a	_	_	
27-36	3857-3861	more	_	_	
27-37	3862-3869	uniform	_	_	
27-38	3870-3872	EB	_	_	
27-39	3872-3873	.	_	_	

#Text=Lastly, in all these methodologies, the cell aggregates are not made from single cell suspensions of pluripotent stem cells as the present invention.
#Text=[0092] Embryoid bodies are cell aggregates, unlike the cell aggregates described in this invention, that are made up of numerous cell types from the three germ layers and are typically created by exposing aggregates of undifferentiated ES cells to non-directed differentiation signals, such as 20% fetal bovine serum.
28-1	3874-3880	Lastly	_	_	
28-2	3880-3881	,	_	_	
28-3	3882-3884	in	_	_	
28-4	3885-3888	all	_	_	
28-5	3889-3894	these	_	_	
28-6	3895-3908	methodologies	_	_	
28-7	3908-3909	,	_	_	
28-8	3910-3913	the	_	_	
28-9	3914-3918	cell	_	_	
28-10	3919-3929	aggregates	_	_	
28-11	3930-3933	are	_	_	
28-12	3934-3937	not	_	_	
28-13	3938-3942	made	_	_	
28-14	3943-3947	from	_	_	
28-15	3948-3954	single	_	_	
28-16	3955-3959	cell	_	_	
28-17	3960-3971	suspensions	_	_	
28-18	3972-3974	of	_	_	
28-19	3975-3986	pluripotent	_	_	
28-20	3987-3991	stem	_	_	
28-21	3992-3997	cells	_	_	
28-22	3998-4000	as	_	_	
28-23	4001-4004	the	_	_	
28-24	4005-4012	present	_	_	
28-25	4013-4022	invention	_	_	
28-26	4022-4023	.	_	_	
28-27	4024-4025	[	_	_	
28-28	4025-4029	0092	_	_	
28-29	4029-4030	]	_	_	
28-30	4031-4039	Embryoid	_	_	
28-31	4040-4046	bodies	_	_	
28-32	4047-4050	are	_	_	
28-33	4051-4055	cell	_	_	
28-34	4056-4066	aggregates	_	_	
28-35	4066-4067	,	_	_	
28-36	4068-4074	unlike	_	_	
28-37	4075-4078	the	_	_	
28-38	4079-4083	cell	_	_	
28-39	4084-4094	aggregates	_	_	
28-40	4095-4104	described	_	_	
28-41	4105-4107	in	_	_	
28-42	4108-4112	this	_	_	
28-43	4113-4122	invention	_	_	
28-44	4122-4123	,	_	_	
28-45	4124-4128	that	_	_	
28-46	4129-4132	are	_	_	
28-47	4133-4137	made	_	_	
28-48	4138-4140	up	_	_	
28-49	4141-4143	of	_	_	
28-50	4144-4152	numerous	_	_	
28-51	4153-4157	cell	_	_	
28-52	4158-4163	types	_	_	
28-53	4164-4168	from	_	_	
28-54	4169-4172	the	_	_	
28-55	4173-4178	three	_	_	
28-56	4179-4183	germ	_	_	
28-57	4184-4190	layers	_	_	
28-58	4191-4194	and	_	_	
28-59	4195-4198	are	_	_	
28-60	4199-4208	typically	_	_	
28-61	4209-4216	created	_	_	
28-62	4217-4219	by	_	_	
28-63	4220-4228	exposing	_	_	
28-64	4229-4239	aggregates	_	_	
28-65	4240-4242	of	_	_	
28-66	4243-4259	undifferentiated	_	_	
28-67	4260-4262	ES	_	_	
28-68	4263-4268	cells	_	_	
28-69	4269-4271	to	_	_	
28-70	4272-4284	non-directed	_	_	
28-71	4285-4300	differentiation	_	_	
28-72	4301-4308	signals	_	_	
28-73	4308-4309	,	_	_	
28-74	4310-4314	such	_	_	
28-75	4315-4317	as	_	_	
28-76	4318-4321	20%	_	_	
28-77	4322-4327	fetal	_	_	
28-78	4328-4334	bovine	_	_	
28-79	4335-4340	serum	_	_	
28-80	4340-4341	.	_	_	

#Text=The result of this non-directed methodology is a mixture of cell types that is intended to mimic normal embryo development in vitro.
29-1	4342-4345	The	_	_	
29-2	4346-4352	result	_	_	
29-3	4353-4355	of	_	_	
29-4	4356-4360	this	_	_	
29-5	4361-4373	non-directed	_	_	
29-6	4374-4385	methodology	_	_	
29-7	4386-4388	is	_	_	
29-8	4389-4390	a	_	_	
29-9	4391-4398	mixture	_	_	
29-10	4399-4401	of	_	_	
29-11	4402-4406	cell	_	_	
29-12	4407-4412	types	_	_	
29-13	4413-4417	that	_	_	
29-14	4418-4420	is	_	_	
29-15	4421-4429	intended	_	_	
29-16	4430-4432	to	_	_	
29-17	4433-4438	mimic	_	_	
29-18	4439-4445	normal	_	_	
29-19	4446-4452	embryo	_	_	
29-20	4453-4464	development	_	_	
29-21	4465-4467	in	_	_	
29-22	4468-4473	vitro	_	_	
29-23	4473-4474	.	_	_	

#Text=While this approach is useful at the basic research level for examining embryo development, it is not amenable to any large-scale cell therapy manufacturing process where cell yield, population identity, population purity, batch consistency, safety, cell function and cost of goods are primary concerns.
30-1	4475-4480	While	_	_	
30-2	4481-4485	this	_	_	
30-3	4486-4494	approach	_	_	
30-4	4495-4497	is	_	_	
30-5	4498-4504	useful	_	_	
30-6	4505-4507	at	_	_	
30-7	4508-4511	the	_	_	
30-8	4512-4517	basic	_	_	
30-9	4518-4526	research	_	_	
30-10	4527-4532	level	_	_	
30-11	4533-4536	for	_	_	
30-12	4537-4546	examining	_	_	
30-13	4547-4553	embryo	_	_	
30-14	4554-4565	development	_	_	
30-15	4565-4566	,	_	_	
30-16	4567-4569	it	_	_	
30-17	4570-4572	is	_	_	
30-18	4573-4576	not	_	_	
30-19	4577-4585	amenable	_	_	
30-20	4586-4588	to	_	_	
30-21	4589-4592	any	_	_	
30-22	4593-4604	large-scale	_	_	
30-23	4605-4609	cell	_	_	
30-24	4610-4617	therapy	_	_	
30-25	4618-4631	manufacturing	_	_	
30-26	4632-4639	process	_	_	
30-27	4640-4645	where	_	_	
30-28	4646-4650	cell	_	_	
30-29	4651-4656	yield	_	_	
30-30	4656-4657	,	_	_	
30-31	4658-4668	population	_	_	
30-32	4669-4677	identity	_	_	
30-33	4677-4678	,	_	_	
30-34	4679-4689	population	_	_	
30-35	4690-4696	purity	_	_	
30-36	4696-4697	,	_	_	
30-37	4698-4703	batch	_	_	
30-38	4704-4715	consistency	_	_	
30-39	4715-4716	,	_	_	
30-40	4717-4723	safety	_	_	
30-41	4723-4724	,	_	_	
30-42	4725-4729	cell	_	_	
30-43	4730-4738	function	_	_	
30-44	4739-4742	and	_	_	
30-45	4743-4747	cost	_	_	
30-46	4748-4750	of	_	_	
30-47	4751-4756	goods	_	_	
30-48	4757-4760	are	_	_	
30-49	4761-4768	primary	_	_	
30-50	4769-4777	concerns	_	_	
30-51	4777-4778	.	_	_	

#Text=Moreover, regardless of any enrichment strategies employed to purify a given cell type from an embryoid body, the differentiation protocol does not provide a directed approach that will generate a large population of a single cell types.
31-1	4779-4787	Moreover	_	_	
31-2	4787-4788	,	_	_	
31-3	4789-4799	regardless	_	_	
31-4	4800-4802	of	_	_	
31-5	4803-4806	any	_	_	
31-6	4807-4817	enrichment	_	_	
31-7	4818-4828	strategies	_	_	
31-8	4829-4837	employed	_	_	
31-9	4838-4840	to	_	_	
31-10	4841-4847	purify	_	_	
31-11	4848-4849	a	_	_	
31-12	4850-4855	given	_	_	
31-13	4856-4860	cell	_	_	
31-14	4861-4865	type	_	_	
31-15	4866-4870	from	_	_	
31-16	4871-4873	an	_	_	
31-17	4874-4882	embryoid	_	_	
31-18	4883-4887	body	_	_	
31-19	4887-4888	,	_	_	
31-20	4889-4892	the	_	_	
31-21	4893-4908	differentiation	_	_	
31-22	4909-4917	protocol	_	_	
31-23	4918-4922	does	_	_	
31-24	4923-4926	not	_	_	
31-25	4927-4934	provide	_	_	
31-26	4935-4936	a	_	_	
31-27	4937-4945	directed	_	_	
31-28	4946-4954	approach	_	_	
31-29	4955-4959	that	_	_	
31-30	4960-4964	will	_	_	
31-31	4965-4973	generate	_	_	
31-32	4974-4975	a	_	_	
31-33	4976-4981	large	_	_	
31-34	4982-4992	population	_	_	
31-35	4993-4995	of	_	_	
31-36	4996-4997	a	_	_	
31-37	4998-5004	single	_	_	
31-38	5005-5009	cell	_	_	
31-39	5010-5015	types	_	_	
31-40	5015-5016	.	_	_	

#Text=Subsequently, contaminant populations will always predominate and will hamper any attempt to purify a specific population.
32-1	5017-5029	Subsequently	_	_	
32-2	5029-5030	,	_	_	
32-3	5031-5042	contaminant	_	_	
32-4	5043-5054	populations	_	_	
32-5	5055-5059	will	_	_	
32-6	5060-5066	always	_	_	
32-7	5067-5078	predominate	_	_	
32-8	5079-5082	and	_	_	
32-9	5083-5087	will	_	_	
32-10	5088-5094	hamper	_	_	
32-11	5095-5098	any	_	_	
32-12	5099-5106	attempt	_	_	
32-13	5107-5109	to	_	_	
32-14	5110-5116	purify	_	_	
32-15	5117-5118	a	_	_	
32-16	5119-5127	specific	_	_	
32-17	5128-5138	population	_	_	
32-18	5138-5139	.	_	_	

#Text=All previous work on creating and differentiating aggregates of ES cells has one or more of the following components in their methodology: 1) use of mouse rather than human ES cells, 2) forced aggregation protocols that rely on centrifugation to aggregate cells rather than normal cell adhesion processes, 3) aggregation of cell chunks in static conditions, 4) non-single cell dissociation or scraping of cells off surfaces to create aggregates, 5) Non-direct differentiation of cell aggregates using 15-20% fetal calf serum, resulting in the formation of an embryoid body and cell types of all germ layers.
33-1	5140-5143	All	_	_	
33-2	5144-5152	previous	_	_	
33-3	5153-5157	work	_	_	
33-4	5158-5160	on	_	_	
33-5	5161-5169	creating	_	_	
33-6	5170-5173	and	_	_	
33-7	5174-5189	differentiating	_	_	
33-8	5190-5200	aggregates	_	_	
33-9	5201-5203	of	_	_	
33-10	5204-5206	ES	_	_	
33-11	5207-5212	cells	_	_	
33-12	5213-5216	has	_	_	
33-13	5217-5220	one	_	_	
33-14	5221-5223	or	_	_	
33-15	5224-5228	more	_	_	
33-16	5229-5231	of	_	_	
33-17	5232-5235	the	_	_	
33-18	5236-5245	following	_	_	
33-19	5246-5256	components	_	_	
33-20	5257-5259	in	_	_	
33-21	5260-5265	their	_	_	
33-22	5266-5277	methodology	_	_	
33-23	5277-5278	:	_	_	
33-24	5279-5280	1	_	_	
33-25	5280-5281	)	_	_	
33-26	5282-5285	use	_	_	
33-27	5286-5288	of	_	_	
33-28	5289-5294	mouse	_	_	
33-29	5295-5301	rather	_	_	
33-30	5302-5306	than	_	_	
33-31	5307-5312	human	_	_	
33-32	5313-5315	ES	_	_	
33-33	5316-5321	cells	_	_	
33-34	5321-5322	,	_	_	
33-35	5323-5324	2	_	_	
33-36	5324-5325	)	_	_	
33-37	5326-5332	forced	_	_	
33-38	5333-5344	aggregation	_	_	
33-39	5345-5354	protocols	_	_	
33-40	5355-5359	that	_	_	
33-41	5360-5364	rely	_	_	
33-42	5365-5367	on	_	_	
33-43	5368-5382	centrifugation	_	_	
33-44	5383-5385	to	_	_	
33-45	5386-5395	aggregate	_	_	
33-46	5396-5401	cells	_	_	
33-47	5402-5408	rather	_	_	
33-48	5409-5413	than	_	_	
33-49	5414-5420	normal	_	_	
33-50	5421-5425	cell	_	_	
33-51	5426-5434	adhesion	_	_	
33-52	5435-5444	processes	_	_	
33-53	5444-5445	,	_	_	
33-54	5446-5447	3	_	_	
33-55	5447-5448	)	_	_	
33-56	5449-5460	aggregation	_	_	
33-57	5461-5463	of	_	_	
33-58	5464-5468	cell	_	_	
33-59	5469-5475	chunks	_	_	
33-60	5476-5478	in	_	_	
33-61	5479-5485	static	_	_	
33-62	5486-5496	conditions	_	_	
33-63	5496-5497	,	_	_	
33-64	5498-5499	4	_	_	
33-65	5499-5500	)	_	_	
33-66	5501-5511	non-single	_	_	
33-67	5512-5516	cell	_	_	
33-68	5517-5529	dissociation	_	_	
33-69	5530-5532	or	_	_	
33-70	5533-5541	scraping	_	_	
33-71	5542-5544	of	_	_	
33-72	5545-5550	cells	_	_	
33-73	5551-5554	off	_	_	
33-74	5555-5563	surfaces	_	_	
33-75	5564-5566	to	_	_	
33-76	5567-5573	create	_	_	
33-77	5574-5584	aggregates	_	_	
33-78	5584-5585	,	_	_	
33-79	5586-5587	5	_	_	
33-80	5587-5588	)	_	_	
33-81	5589-5599	Non-direct	_	_	
33-82	5600-5615	differentiation	_	_	
33-83	5616-5618	of	_	_	
33-84	5619-5623	cell	_	_	
33-85	5624-5634	aggregates	_	_	
33-86	5635-5640	using	_	_	
33-87	5641-5643	15	_	_	
33-88	5643-5644	-	_	_	
33-89	5644-5647	20%	_	_	
33-90	5648-5653	fetal	_	_	
33-91	5654-5658	calf	_	_	
33-92	5659-5664	serum	_	_	
33-93	5664-5665	,	_	_	
33-94	5666-5675	resulting	_	_	
33-95	5676-5678	in	_	_	
33-96	5679-5682	the	_	_	
33-97	5683-5692	formation	_	_	
33-98	5693-5695	of	_	_	
33-99	5696-5698	an	_	_	
33-100	5699-5707	embryoid	_	_	
33-101	5708-5712	body	_	_	
33-102	5713-5716	and	_	_	
33-103	5717-5721	cell	_	_	
33-104	5722-5727	types	_	_	
33-105	5728-5730	of	_	_	
33-106	5731-5734	all	_	_	
33-107	5735-5739	germ	_	_	
33-108	5740-5746	layers	_	_	
33-109	5746-5747	.	_	_	

#Text=To our knowledge, the only study that does not utilize 15-20% FCS to differentiate embryoid bodies describes a protocol where cell aggregates are formed by forced aggregation then aggregates are immediately differentiated using media appropriate for mesoderm (Ng et al., Blood 2005 106(5):1601).
34-1	5748-5750	To	_	_	
34-2	5751-5754	our	_	_	
34-3	5755-5764	knowledge	_	_	
34-4	5764-5765	,	_	_	
34-5	5766-5769	the	_	_	
34-6	5770-5774	only	_	_	
34-7	5775-5780	study	_	_	
34-8	5781-5785	that	_	_	
34-9	5786-5790	does	_	_	
34-10	5791-5794	not	_	_	
34-11	5795-5802	utilize	_	_	
34-12	5803-5805	15	_	_	
34-13	5805-5806	-	_	_	
34-14	5806-5809	20%	_	_	
34-15	5810-5813	FCS	_	_	
34-16	5814-5816	to	_	_	
34-17	5817-5830	differentiate	_	_	
34-18	5831-5839	embryoid	_	_	
34-19	5840-5846	bodies	_	_	
34-20	5847-5856	describes	_	_	
34-21	5857-5858	a	_	_	
34-22	5859-5867	protocol	_	_	
34-23	5868-5873	where	_	_	
34-24	5874-5878	cell	_	_	
34-25	5879-5889	aggregates	_	_	
34-26	5890-5893	are	_	_	
34-27	5894-5900	formed	_	_	
34-28	5901-5903	by	_	_	
34-29	5904-5910	forced	_	_	
34-30	5911-5922	aggregation	_	_	
34-31	5923-5927	then	_	_	
34-32	5928-5938	aggregates	_	_	
34-33	5939-5942	are	_	_	
34-34	5943-5954	immediately	_	_	
34-35	5955-5969	differentiated	_	_	
34-36	5970-5975	using	_	_	
34-37	5976-5981	media	_	_	
34-38	5982-5993	appropriate	_	_	
34-39	5994-5997	for	_	_	
34-40	5998-6006	mesoderm	_	_	
34-41	6007-6008	(	_	_	
34-42	6008-6010	Ng	_	_	
34-43	6011-6013	et	_	_	
34-44	6014-6016	al	_	_	
34-45	6016-6017	.	_	_	
34-46	6017-6018	,	_	_	
34-47	6019-6024	Blood	_	_	
34-48	6025-6029	2005	_	_	
34-49	6030-6033	106	_	_	
34-50	6033-6034	(	_	_	
34-51	6034-6035	5	_	_	
34-52	6035-6036	)	_	_	
34-53	6036-6037	:	_	_	
34-54	6037-6041	1601	_	_	
34-55	6041-6042	)	_	_	
34-56	6042-6043	.	_	_	

#Text=However, in this work, the researchers transferred the embryoid bodies to non-aggregate adherent culture after 10-12 days in static aggregate culture making comparisons to the current application irrelevant.
35-1	6044-6051	However	_	_	
35-2	6051-6052	,	_	_	
35-3	6053-6055	in	_	_	
35-4	6056-6060	this	_	_	
35-5	6061-6065	work	_	_	
35-6	6065-6066	,	_	_	
35-7	6067-6070	the	_	_	
35-8	6071-6082	researchers	_	_	
35-9	6083-6094	transferred	_	_	
35-10	6095-6098	the	_	_	
35-11	6099-6107	embryoid	_	_	
35-12	6108-6114	bodies	_	_	
35-13	6115-6117	to	_	_	
35-14	6118-6131	non-aggregate	_	_	
35-15	6132-6140	adherent	_	_	
35-16	6141-6148	culture	_	_	
35-17	6149-6154	after	_	_	
35-18	6155-6157	10	_	_	
35-19	6157-6158	-	_	_	
35-20	6158-6160	12	_	_	
35-21	6161-6165	days	_	_	
35-22	6166-6168	in	_	_	
35-23	6169-6175	static	_	_	
35-24	6176-6185	aggregate	_	_	
35-25	6186-6193	culture	_	_	
35-26	6194-6200	making	_	_	
35-27	6201-6212	comparisons	_	_	
35-28	6213-6215	to	_	_	
35-29	6216-6219	the	_	_	
35-30	6220-6227	current	_	_	
35-31	6228-6239	application	_	_	
35-32	6240-6250	irrelevant	_	_	
35-33	6250-6251	.	_	_	

#Text=In contrast to all previous work, the current application presents an approach that 1) dissociates human ES cells to single cells then creates aggregates by rotational culture at shear rates optimized for improve control of aggregate diameter and cell survival, 2) directly differentiates the ES cell aggregates to definitive endoderm then foregut endoderm, then pre-pancreatic foregut endoderm, then pancreatic endoderm and finally pancreatic endocrine cells.
36-1	6252-6254	In	_	_	
36-2	6255-6263	contrast	_	_	
36-3	6264-6266	to	_	_	
36-4	6267-6270	all	_	_	
36-5	6271-6279	previous	_	_	
36-6	6280-6284	work	_	_	
36-7	6284-6285	,	_	_	
36-8	6286-6289	the	_	_	
36-9	6290-6297	current	_	_	
36-10	6298-6309	application	_	_	
36-11	6310-6318	presents	_	_	
36-12	6319-6321	an	_	_	
36-13	6322-6330	approach	_	_	
36-14	6331-6335	that	_	_	
36-15	6336-6337	1	_	_	
36-16	6337-6338	)	_	_	
36-17	6339-6350	dissociates	_	_	
36-18	6351-6356	human	_	_	
36-19	6357-6359	ES	_	_	
36-20	6360-6365	cells	_	_	
36-21	6366-6368	to	_	_	
36-22	6369-6375	single	_	_	
36-23	6376-6381	cells	_	_	
36-24	6382-6386	then	_	_	
36-25	6387-6394	creates	_	_	
36-26	6395-6405	aggregates	_	_	
36-27	6406-6408	by	_	_	
36-28	6409-6419	rotational	_	_	
36-29	6420-6427	culture	_	_	
36-30	6428-6430	at	_	_	
36-31	6431-6436	shear	_	_	
36-32	6437-6442	rates	_	_	
36-33	6443-6452	optimized	_	_	
36-34	6453-6456	for	_	_	
36-35	6457-6464	improve	_	_	
36-36	6465-6472	control	_	_	
36-37	6473-6475	of	_	_	
36-38	6476-6485	aggregate	_	_	
36-39	6486-6494	diameter	_	_	
36-40	6495-6498	and	_	_	
36-41	6499-6503	cell	_	_	
36-42	6504-6512	survival	_	_	
36-43	6512-6513	,	_	_	
36-44	6514-6515	2	_	_	
36-45	6515-6516	)	_	_	
36-46	6517-6525	directly	_	_	
36-47	6526-6540	differentiates	_	_	
36-48	6541-6544	the	_	_	
36-49	6545-6547	ES	_	_	
36-50	6548-6552	cell	_	_	
36-51	6553-6563	aggregates	_	_	
36-52	6564-6566	to	_	_	
36-53	6567-6577	definitive	_	_	
36-54	6578-6586	endoderm	_	_	
36-55	6587-6591	then	_	_	
36-56	6592-6599	foregut	_	_	
36-57	6600-6608	endoderm	_	_	
36-58	6608-6609	,	_	_	
36-59	6610-6614	then	_	_	
36-60	6615-6629	pre-pancreatic	_	_	
36-61	6630-6637	foregut	_	_	
36-62	6638-6646	endoderm	_	_	
36-63	6646-6647	,	_	_	
36-64	6648-6652	then	_	_	
36-65	6653-6663	pancreatic	_	_	
36-66	6664-6672	endoderm	_	_	
36-67	6673-6676	and	_	_	
36-68	6677-6684	finally	_	_	
36-69	6685-6695	pancreatic	_	_	
36-70	6696-6705	endocrine	_	_	
36-71	6706-6711	cells	_	_	
36-72	6711-6712	.	_	_	

#Text=This differentiation protocol generates definitive endoderm and pancreatic lineage populations with high efficiency and minimal contaminant populations.
37-1	6713-6717	This	_	_	
37-2	6718-6733	differentiation	_	_	
37-3	6734-6742	protocol	_	_	
37-4	6743-6752	generates	_	_	
37-5	6753-6763	definitive	_	_	
37-6	6764-6772	endoderm	_	_	
37-7	6773-6776	and	_	_	
37-8	6777-6787	pancreatic	_	_	
37-9	6788-6795	lineage	_	_	
37-10	6796-6807	populations	_	_	
37-11	6808-6812	with	_	_	
37-12	6813-6817	high	_	_	
37-13	6818-6828	efficiency	_	_	
37-14	6829-6832	and	_	_	
37-15	6833-6840	minimal	_	_	
37-16	6841-6852	contaminant	_	_	
37-17	6853-6864	populations	_	_	
37-18	6864-6865	.	_	_	

#Text=Moreover, this approach to ES cell aggregation and differentiation does not create embryoid bodies, in direct contrast to all other published research.
#Text=[0093] In contrast to embryoid bodies, which are a mixture of differentiated and undifferentiated cells and typically consist of cells from several germ layers and go through random differentiation, the cell aggregates described herein are essentially or substantially homo-cellular, existing as aggregates of pluripotent, multipotent, bipotent, or unipotent type cells, e.g., embryonic cells, definitive endoderm, foregut endoderm, PDX1 positive pancreatic endoderm, pancreatic endocrine cells and the like.
38-1	6866-6874	Moreover	_	_	
38-2	6874-6875	,	_	_	
38-3	6876-6880	this	_	_	
38-4	6881-6889	approach	_	_	
38-5	6890-6892	to	_	_	
38-6	6893-6895	ES	_	_	
38-7	6896-6900	cell	_	_	
38-8	6901-6912	aggregation	_	_	
38-9	6913-6916	and	_	_	
38-10	6917-6932	differentiation	_	_	
38-11	6933-6937	does	_	_	
38-12	6938-6941	not	_	_	
38-13	6942-6948	create	_	_	
38-14	6949-6957	embryoid	_	_	
38-15	6958-6964	bodies	_	_	
38-16	6964-6965	,	_	_	
38-17	6966-6968	in	_	_	
38-18	6969-6975	direct	_	_	
38-19	6976-6984	contrast	_	_	
38-20	6985-6987	to	_	_	
38-21	6988-6991	all	_	_	
38-22	6992-6997	other	_	_	
38-23	6998-7007	published	_	_	
38-24	7008-7016	research	_	_	
38-25	7016-7017	.	_	_	
38-26	7018-7019	[	_	_	
38-27	7019-7023	0093	_	_	
38-28	7023-7024	]	_	_	
38-29	7025-7027	In	_	_	
38-30	7028-7036	contrast	_	_	
38-31	7037-7039	to	_	_	
38-32	7040-7048	embryoid	_	_	
38-33	7049-7055	bodies	_	_	
38-34	7055-7056	,	_	_	
38-35	7057-7062	which	_	_	
38-36	7063-7066	are	_	_	
38-37	7067-7068	a	_	_	
38-38	7069-7076	mixture	_	_	
38-39	7077-7079	of	_	_	
38-40	7080-7094	differentiated	_	_	
38-41	7095-7098	and	_	_	
38-42	7099-7115	undifferentiated	_	_	
38-43	7116-7121	cells	_	_	
38-44	7122-7125	and	_	_	
38-45	7126-7135	typically	_	_	
38-46	7136-7143	consist	_	_	
38-47	7144-7146	of	_	_	
38-48	7147-7152	cells	_	_	
38-49	7153-7157	from	_	_	
38-50	7158-7165	several	_	_	
38-51	7166-7170	germ	_	_	
38-52	7171-7177	layers	_	_	
38-53	7178-7181	and	_	_	
38-54	7182-7184	go	_	_	
38-55	7185-7192	through	_	_	
38-56	7193-7199	random	_	_	
38-57	7200-7215	differentiation	_	_	
38-58	7215-7216	,	_	_	
38-59	7217-7220	the	_	_	
38-60	7221-7225	cell	_	_	
38-61	7226-7236	aggregates	_	_	
38-62	7237-7246	described	_	_	
38-63	7247-7253	herein	_	_	
38-64	7254-7257	are	_	_	
38-65	7258-7269	essentially	_	_	
38-66	7270-7272	or	_	_	
38-67	7273-7286	substantially	_	_	
38-68	7287-7300	homo-cellular	_	_	
38-69	7300-7301	,	_	_	
38-70	7302-7310	existing	_	_	
38-71	7311-7313	as	_	_	
38-72	7314-7324	aggregates	_	_	
38-73	7325-7327	of	_	_	
38-74	7328-7339	pluripotent	_	_	
38-75	7339-7340	,	_	_	
38-76	7341-7352	multipotent	_	_	
38-77	7352-7353	,	_	_	
38-78	7354-7362	bipotent	_	_	
38-79	7362-7363	,	_	_	
38-80	7364-7366	or	_	_	
38-81	7367-7376	unipotent	_	_	
38-82	7377-7381	type	_	_	
38-83	7382-7387	cells	_	_	
38-84	7387-7388	,	_	_	
38-85	7389-7392	e.g	_	_	
38-86	7392-7393	.	_	_	
38-87	7393-7394	,	_	_	
38-88	7395-7404	embryonic	_	_	
38-89	7405-7410	cells	_	_	
38-90	7410-7411	,	_	_	
38-91	7412-7422	definitive	_	_	
38-92	7423-7431	endoderm	_	_	
38-93	7431-7432	,	_	_	
38-94	7433-7440	foregut	_	_	
38-95	7441-7449	endoderm	_	_	
38-96	7449-7450	,	_	_	
38-97	7451-7455	PDX1	_	_	
38-98	7456-7464	positive	_	_	
38-99	7465-7475	pancreatic	_	_	
38-100	7476-7484	endoderm	_	_	
38-101	7484-7485	,	_	_	
38-102	7486-7496	pancreatic	_	_	
38-103	7497-7506	endocrine	_	_	
38-104	7507-7512	cells	_	_	
38-105	7513-7516	and	_	_	
38-106	7517-7520	the	_	_	
38-107	7521-7525	like	_	_	
38-108	7525-7526	.	_	_	
